Signal active
Organization
Contact Information
Overview
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.
The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
About
Biotechnology, Health Care, Therapeutics
2007
51-100
Headquarters locations
Europe
Social
N/A
Profile Resume
Crescendo Biologics headquartered in Europe, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $14.2B in funding across 96 round(s). With a team of 51-100 employees, Crescendo Biologics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Crescendo Biologics, raised $7.3M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
8
4
0
$148.2M
Details
5
Crescendo Biologics has raised a total of $148.2M in funding over 5 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2018 | Early Stage Venture | 70.0M | ||
2014 | Early Stage Venture | 3.3M | ||
2013 | Early Stage Venture | 28.5M | ||
2010 | Early Stage Venture | 7.3M |
Investors
Crescendo Biologics is funded by 29 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Crescendo Biologics | - | FUNDING ROUND - Crescendo Biologics | 32.0M |
Andera Partners | - | FUNDING ROUND - Andera Partners | 32.0M |
Crescendo Biologics | - | FUNDING ROUND - Crescendo Biologics | 7.3M |
Future Planet Capital | - | FUNDING ROUND - Future Planet Capital | 7.3M |
Recent Activity
There is no recent news or activity for this profile.